Daily FNArena News - Small Caps

The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA

Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports

The New Criterion’s Tim Boreham explains the benefits of royalties and where to access them via the ASX

Tim Boreham highlights Hydrix as one of the most innovative small-cap healthcare companies on the ASX

Brokers welcome Life360’s new advertising initiative unveiled at the same time as FY23 results and FY24 guidance which both exceeded expectations

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked

Dicker data shares fell -10% yesterday but it had nothing to do with the company’s AI-fuelled outlook

Profit season brings out the best and worst in small caps, and sometimes both at once, reports The New Criterion’s Tim Boreham

A disappointing update on recently acquired powercloud does not ruin the investment case for Hansen Technologies, analysts say